WHO approves Chinese vaccines for emergency use
Simon Collins, HIV i-Base
On 1 June 2020, the WHO approved the Chinese CoronaVac (Sinovac) vaccine against COVID-19. 
This was based on limited research that included 51% efficacy against symptomatic infection and 100% efficacy at preventing hospitalisation and death.
Phase 3 studies are currently ongoing in Brazil, Chile, Indonesia, and Turkey and results from a large prospective national vaccine programme in Chile were just published in the NEJM. 
This is the second Chinese vaccine to be given WHO emergency use approval. On 7 May 2020, the WHO approved the Sinopharm vaccine developed by the Beijing Institute of Biological Products. 
Both vaccines have already been widely used in low-income countries. However, WHO approval means they can be included in the international COVAX programme. Both vaccines use inactivated virus.
The WHO have also approved vaccines by Pfizer, AstraZeneca, Johnson & Johnson, Moderna and the Serum Institute of India (CoviShield). 
- WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. (1 June 2021).
- Jara A et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. NEJM. DOI: 10.1056/NEJMoa2107715. (7 July 2021).
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. (7 May 2021).
- WHO. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. (2 July 2021).
This report was first published on 7 July 2021.